Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 01, 2021

Zanubrutinib Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
The Magnolia Trial: Zanubrutinib, A Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Clin. Cancer Res 2021 Sep 15;na(na)na, S Opat, A Tedeschi, K Linton, P McKay, B Hu, H Chan, J Jin, M Sobieraj-Teague, PL Zinzani, M Coleman, C Thieblemont, P Browett, X Ke, M Sun, R Marcus, CA Portell, K Ardeshna, F Bijou, P Walker, EA Hawkes, S Mapp, SJ Ho, D Talaulikar, KS Zhou, M Co, X Li, W Zhou, M Cappellini, C Tankersley, J Huang, J Trotman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading